The rise of Viagra and its effect on the pharmaceutical landscape presents a intricate question for traders. While the early sales data were astounding, the exclusivity has ended, leading to a wave of copycat alternatives that are chipping away at revenue. Furthermore, the industry is facing challenges related to aging trends and shifting healthcar